Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study
Identifieur interne : 000260 ( PascalFrancis/Checkpoint ); précédent : 000259; suivant : 000261Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study
Auteurs : Valerie Voon [Royaume-Uni] ; Mandy Sohr [Allemagne] ; Anthony E. Lang [Canada] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Jacqueline Whetteckey [États-Unis] ; Daniel Weintraub [États-Unis] ; Glen R. Wunderlich [Canada] ; Mark Stacy [États-Unis]Source :
- Annals of neurology [ 0364-5134 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.
Affiliations:
- Allemagne, Canada, Royaume-Uni, États-Unis
- Angleterre, Angleterre de l'Est, Ontario
- Cambridge, Toronto
- Université de Cambridge, Université de Toronto
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:11-0316997Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study</title><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Behavioral and Clinical Neurosciences Institute, University of Cambridge</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName><orgName type="university">Université de Cambridge</orgName></affiliation></author><author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Boehringer Ingelheim Pharma</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Haven, CT</wicri:noRegion></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Philadelphia, PA</wicri:noRegion></affiliation></author><author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharmaceuticals</s1><s2>Ridgefield, CT</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Boehringer Ingelheim Pharmaceuticals</wicri:noRegion></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Philadelphia, PA</wicri:noRegion></affiliation></author><author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada)</s1><s2>Burlington, Ontario</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Boehringer Ingelheim (Canada)</wicri:noRegion></affiliation></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Duke University Medical Center</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Durham, NC</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0316997</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0316997 INIST</idno><idno type="RBID">Pascal:11-0316997</idno><idno type="wicri:Area/PascalFrancis/Corpus">000308</idno><idno type="wicri:Area/PascalFrancis/Curation">000955</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000260</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000260</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study</title><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Behavioral and Clinical Neurosciences Institute, University of Cambridge</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName><orgName type="university">Université de Cambridge</orgName></affiliation></author><author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Boehringer Ingelheim Pharma</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma</wicri:noRegion><wicri:noRegion>Boehringer Ingelheim Pharma</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Haven, CT</wicri:noRegion></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Philadelphia, PA</wicri:noRegion></affiliation></author><author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharmaceuticals</s1><s2>Ridgefield, CT</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Boehringer Ingelheim Pharmaceuticals</wicri:noRegion></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Philadelphia, PA</wicri:noRegion></affiliation></author><author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada)</s1><s2>Burlington, Ontario</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Boehringer Ingelheim (Canada)</wicri:noRegion></affiliation></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Duke University Medical Center</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Durham, NC</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Case control study</term><term>Impulse control disorder</term><term>Multicenter study</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Trouble du contrôle des impulsions</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Etude multicentrique</term><term>Etude cas témoin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0></fA01><fA02 i1="01"><s0>ANNED3</s0></fA02><fA03 i2="1"><s0>Ann. neurol.</s0></fA03><fA05><s2>69</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study</s1></fA08><fA11 i1="01" i2="1"><s1>VOON (Valerie)</s1></fA11><fA11 i1="02" i2="1"><s1>SOHR (Mandy)</s1></fA11><fA11 i1="03" i2="1"><s1>LANG (Anthony E.)</s1></fA11><fA11 i1="04" i2="1"><s1>POTENZA (Marc N.)</s1></fA11><fA11 i1="05" i2="1"><s1>SIDEROWF (Andrew D.)</s1></fA11><fA11 i1="06" i2="1"><s1>WHETTECKEY (Jacqueline)</s1></fA11><fA11 i1="07" i2="1"><s1>WEINTRAUB (Daniel)</s1></fA11><fA11 i1="08" i2="1"><s1>WUNDERLICH (Glen R.)</s1></fA11><fA11 i1="09" i2="1"><s1>STACY (Mark)</s1></fA11><fA14 i1="01"><s1>Behavioral and Clinical Neurosciences Institute, University of Cambridge</s1><s2>Cambridge</s2><s3>GBR</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Boehringer Ingelheim Pharma</s1><s2>Ingelheim</s2><s3>DEU</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Boehringer Ingelheim Pharmaceuticals</s1><s2>Ridgefield, CT</s2><s3>USA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Boehringer Ingelheim (Canada)</s1><s2>Burlington, Ontario</s2><s3>CAN</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Neurology, Duke University Medical Center</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA20><s1>986-996</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>16555</s2><s5>354000190453440120</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>37 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0316997</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of neurology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Trouble du contrôle des impulsions</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Impulse control disorder</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Trastorno control impulso</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Etude multicentrique</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Multicenter study</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Estudio multicéntrico</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Etude cas témoin</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Case control study</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Estudio caso control</s0><s5>10</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>213</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Angleterre de l'Est</li><li>Ontario</li></region><settlement><li>Cambridge</li><li>Toronto</li></settlement><orgName><li>Université de Cambridge</li><li>Université de Toronto</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name></region></country><country name="Allemagne"><noRegion><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name></noRegion></country><country name="Canada"><region name="Ontario"><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></region><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name></country><country name="États-Unis"><noRegion><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name></noRegion><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:11-0316997
|texte= Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study
}}
| This area was generated with Dilib version V0.6.29. |  |